Cost-Effectiveness of Testing and Screening Strategies for Trichomoniasis among Asymptomatic and Symptomatic Women in U.S. Outpatient Clinical Settings.

Authors

Rong Rong, Charles Stoecker, Patricia J Kissinger, Christina A Muzny

Published in

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. Aug 08, 2026. Epub Aug 08, 2026.

Abstract

T. vaginalis, the most common non-viral sexually transmitted infection among women, is associated with multiple adverse health outcomes. Screening asymptomatic women is not recommended except among HIV-infected women. We aimed to evaluate the cost-effectiveness of T. vaginalis testing and screening strategies among asymptomatic and symptomatic women, respectively, in U.S. primary care settings.
We developed a decision tree model to evaluate 11 testing/screening strategies (using combinations of wet mount microscopy, rapid antigen testing, and T. vaginalis nucleic acid amplification testing [NAAT]) for a hypothetical cohort of 8,000 women aged 15-59 years presenting to U.S. primary care clinics in 2023. We estimated the risk, societal economic burden, and quality-adjusted life year (QALY) losses for trichomonas sequelae-preterm birth, low birthweight, premature rupture of membranes, HIV infection, and cervical cancer-over the cohort's lifetime.
Adding T. vaginalis NAAT to wet mount for symptomatic women provided 0.3 additional QALYs at an incremental cost of $24,785 (ICER: $83,097/QALY). Adding NAAT to rapid antigen testing for symptomatic women yielded 0.1 additional QALYs at an incremental cost of $35,628 (ICER: $324,617/QALY). Screening asymptomatic women with NAAT cost $403,541/QALY.
Incorporating NAAT into current testing practices for symptomatic women improved health outcomes but increased costs. At a willingness-to-pay threshold of $100,000/QALY, adding NAAT to wet mount for symptomatic women was cost-effective whereas adding NAAT to rapid antigen testing was not. Universal NAAT screening among asymptomatic women was also not cost-effective, suggesting that broader screening strategies may require substantially higher willingness-to-pay thresholds to be economically justified.

PMID:
42570009
Bibliographic data and abstract were imported from PubMed on 09 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.